The Drug Enforcement Administration has registered medical marijuana dispensaries operated by Trulieve Cannabis Corp. as federally compliant under Schedule III of the Controlled Substances Act, the Florida-based multistate operator announced Monday. The move marks the first major test of federal recognition for cannabis businesses under the proposed rescheduling framework.
But the DEA simultaneously denied registration to at least one Minnesota adult-use retailer, drawing a clear line between medical and recreational cannabis operations. The rejection signals that federal compliance may remain out of reach for the majority of state-licensed cannabis businesses even if marijuana moves to Schedule III.
Trulieve operates over 180 dispensaries across nine states, primarily focused on medical marijuana markets. The company did not specify how many of its locations received DEA registration or which states were involved. Trulieve also did not disclose whether the registrations apply only to medical-only states or include dual-use markets where the company serves both patient and adult-use customers.
The Schedule III Divide
The contrasting outcomes highlight a fundamental tension in the federal rescheduling process. Moving marijuana from Schedule I to Schedule III would acknowledge accepted medical use, but it wouldn't legalize recreational cannabis at the federal level.
The Minnesota retailer's rejection underscores this distinction. While state-legal adult-use sales have generated billions in tax revenue and created thousands of jobs, those operations remain federally non-compliant even under Schedule III. The retailer was not named in available reports.
Industry attorneys have warned for months that Schedule III won't solve the fundamental conflict between state and federal law for recreational operators. Medical dispensaries in states with tightly regulated programs may find a path to federal registration, but adult-use retailers face continued federal prohibition.
What Federal Registration Means
DEA registration would allow compliant cannabis businesses to access certain federal benefits currently denied under Schedule I. Registered entities could potentially deduct normal business expenses on federal taxes, eliminating the burden of Internal Revenue Code Section 280E that has plagued cannabis operators for years.
Federal recognition could also ease banking restrictions, though questions remain about whether financial institutions will service registered cannabis businesses without explicit safe harbor provisions from banking regulators. The Federal Deposit Insurance Corporation and Federal Reserve have not issued updated guidance on cannabis banking since the rescheduling proposal emerged.
For Trulieve, the registrations could provide significant financial relief. The company reported $303.5 million in revenue for the third quarter of 2024, but like all cannabis operators, it cannot deduct standard business expenses like rent, payroll, and marketing costs on federal returns.
Industry Response
The split decision has drawn mixed reactions across the cannabis sector. Medical marijuana advocates view it as validation of patient-focused programs, while adult-use proponents see it as arbitrary federal gatekeeping that ignores the reality of state-legal markets.
Several multistate operators with significant medical operations, including Curaleaf, Green Thumb Industries, and Verano, may seek similar DEA registrations for their medical dispensaries. But companies focused primarily on adult-use markets, such as many operators in California, Colorado, and Michigan, appear shut out of federal recognition under the current framework.
The National Cannabis Industry Association has not yet issued a statement on the registrations. The organization has previously advocated for comprehensive federal legalization rather than rescheduling, arguing that Schedule III creates more complications than it solves.
What Happens Next
The DEA's final rule on rescheduling marijuana to Schedule III remains pending after a public comment period that drew over 43,000 submissions. The agency has not announced a timeline for finalizing the rule, though industry observers expect a decision in early 2025.
If the rule is finalized as proposed, more medical marijuana operators are expected to apply for DEA registration. But the Trulieve approval and Minnesota rejection suggest the agency will maintain strict boundaries between medical and adult-use operations.
Congress could intervene to clarify federal policy on state-legal cannabis, but comprehensive reform legislation has stalled repeatedly in recent years. The SAFER Banking Act, which would protect financial institutions serving cannabis businesses, passed the House but remains stuck in the Senate.
This article is based on original reporting by mjbizdaily.com.
